Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 12:34 AM ET

Biotechnology

Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment ...

699 Boylston Street

8th Floor

Boston, MA 02116

United States

33 Employees

Phone:

617-600-4313

Key Executives for EPIRUS Biopharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $428.1K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 55
Total Annual Compensation: $292.7K
Chief Technical Officer and Senior Vice President
Age: 59
Total Annual Compensation: $294.2K
Compensation as of Fiscal Year 2014.

EPIRUS Biopharmaceuticals, Inc. Key Developments

EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

EPIRUS Biopharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $45,000. Loss from operations was $15,013,000 compared with $8,948,000 for the same period a year ago. Net loss was $15,286,000 or $0.65 per basic and diluted share compared with $9,890,000 or $28.71 per basic and diluted share for the same period a year ago. For the six months, the company reported revenues of $70,000. Loss from operations was $22,235,000 compared with $15,170,000 for the same period a year ago. Net loss was $22,807,000 or $1.07 per basic and diluted share compared with $17,510,000 or $57.54 per basic and diluted share for the same period a year ago.

Epirus Biopharmaceuticals Signs Multi-Product, Multi-Region Profit-Sharing Collaboration with Polpharma Group

Epirus Biopharmaceuticals announced that it has signed a multi-product, multi-region profit-sharing collaboration with Polpharma Group, for select Epirus biosimilars. The biosimilars covered in the collaboration include BOW015 (infliximab, reference biologic Remicade), BOW050 (adalimumab, reference biologic Humira) and BOW070 (tocilizumab, reference biologic Actemra), which represents $6 billion in innovator sales in the specified territories. With Epirus leading the global product development and clinical programs, both parties will jointly fund clinical development and collaborate on regulatory filings in the specified territories. Epirus will also be responsible for process development, scale-up and manufacturing, with Polpharma Group overseeing commercialization across the territories. Clinical development costs and eventual operating profit will be split 51% Polpharma Group and 49% Epirus. Polpharma Group will contribute about $30 million towards clinical development costs, as well as cover product launch costs across all three programs. Epirus retains the commercial rights to Switzerland and Norway along with select EU countries including Austria, Belgium, Denmark, Finland, Luxembourg, the Netherlands and Sweden, allowing the company to build its direct commercial footprint. Epirus also retains rights to North America and other global markets not addressed in this agreement. A joint management board will oversee the collaboration.

EPIRUS Biopharmaceuticals, Inc. - Special Call

To discuss a multi-product, multi-region profit-sharing collaboration for select EPIRUS biosimilars, including BOW015 (infliximab, reference biologic Remicade), BOW050 (adalimumab, reference biologic Humira) and BOW070 (tocilizumab, reference biologic Actemra)

Similar Private Companies By Industry

Company Name Region
Symbiota, Inc. United States
Trojan Technologies USA, LLC United States
CeraPedics, Inc. United States
Cellerant Therapeutics, Inc. United States
Stem CentRx, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIRUS Biopharmaceuticals, Inc., please visit www.epirusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.